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BACKGROUND
Acute kidney injury is common in critically ill patients, many of whom receive 
renal-replacement therapy. However, the most effective timing for the initiation of 
such therapy remains uncertain.
METHODS
We conducted a multinational, randomized, controlled trial involving critically ill 
patients with severe acute kidney injury. Patients were randomly assigned to re-
ceive an accelerated strategy of renal-replacement therapy (in which therapy was 
initiated within 12 hours after the patient had met eligibility criteria) or a standard 
strategy (in which renal-replacement therapy was discouraged unless conventional 
indications developed or acute kidney injury persisted for >72 hours). The primary 
outcome was death from any cause at 90 days.
RESULTS
Of the 3019 patients who had undergone randomization, 2927 (97.0%) were in-
cluded in the modified intention-to-treat analysis (1465 in the accelerated-strategy 
group and 1462 in the standard-strategy group). Of these patients, renal-replace-
ment therapy was performed in 1418 (96.8%) in the accelerated-strategy group and 
in 903 (61.8%) in the standard-strategy group. At 90 days, death had occurred in 
643 patients (43.9%) in the accelerated-strategy group and in 639 (43.7%) in the 
standard-strategy group (relative risk, 1.00; 95% confidence interval [CI], 0.93 to 
1.09; P = 0.92). Among survivors at 90 days, continued dependence on renal- 
replacement therapy was confirmed in 85 of 814 patients (10.4%) in the accelerated-
strategy group and in 49 of 815 patients (6.0%) in the standard-strategy group 
(relative risk, 1.74; 95% CI, 1.24 to 2.43). Adverse events occurred in 346 of 1503 
patients (23.0%) in the accelerated-strategy group and in 245 of 1489 patients 
(16.5%) in the standard-strategy group (P<0.001).
CONCLUSIONS
Among critically ill patients with acute kidney injury, an accelerated renal-replace-
ment strategy was not associated with a lower risk of death at 90 days than a 
standard strategy. (Funded by the Canadian Institutes of Health Research and 
others; STARRT-AKI ClinicalTrials.gov number, NCT02568722.)
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Acute kidney injury is a common complication in patients admitted to an intensive care unit (ICU) and is associated 
with a high risk of death or major complications 
and a high level of resource use.1 Many patients 
who are seriously ill undergo renal-replacement 
therapy; however, the appropriate timing for the 
initiation of such therapy remains uncertain. 
When acute kidney injury is complicated by ma-
jor metabolic disorders (e.g., acidosis, hyperkale-
mia, and uremia) and fluid disturbances that can 
be treated with renal-replacement therapy, there 
is general consensus that such therapy should be 
initiated.2,3 However, when severe acute kidney 
injury is not accompanied by one of these com-
plications, the benefits of renal-replacement 
therapy are unclear.4-9
The initiation of renal-replacement therapy 
before the onset of major complications has con-
ceivable advantages for patients with severe acute 
kidney injury. Such therapy can restore and 
maintain acid–base homeostasis, mitigate fluid 
accumulation, and reduce exposure to the meta-
bolic hazards of untreated acute kidney injury.10 
However, wide adoption of early renal-replace-
ment therapy in these patients may lead to ini-
tiation in those who would have survived and 
recovered kidney function without such therapy.5 
Furthermore, given the risks of renal-replacement 
therapy, establishing whether earlier initiation can 
improve outcomes is important for patient care. 
Randomized trials that have compared early and 
delayed strategies for starting renal-replacement 
therapy in critically ill patients with acute kidney 
injury have shown discrepant findings.4-7
Here, we report the results of a multinational, 
randomized, open-label, controlled trial (STARRT-
AKI [Standard versus Accelerated Initiation of 
Renal-Replacement Therapy in Acute Kidney In-
jury]) to compare the effect of two strategies 
(accelerated initiation vs. standard initiation) in 
critically ill patients with acute kidney injury. We 
hypothesized that an accelerated strategy for 
renal-replacement therapy would result in a lower 
risk of death from any cause at 90 days than a 
standard strategy.
Me thods
Trial Design and Oversight
We conducted STARRT-AKI at 168 hospitals in 
15 countries. A complete list of participating 
sites is provided in the Supplementary Appendix, 
available with the full text of this article at 
NEJM.org. The protocol along with its statistical 
analysis plan (also available at NEJM.org) was 
published previously.11,12 The investigators de-
signed the trial, wrote the manuscript, and vouch 
for the accuracy and completeness of the data 
and the analyses, for the adherence of the trial 
to the protocol, and for the complete reporting 
of adverse events. The funding organizations 
and partners were not involved in the design, 
implementation, or management of the trial, in 
the analysis of the data, or in the decision to 
submit the manuscript for publication.
Approval for the conduct of the trial was ob-
tained from the institutional review board at 
each participating site. We obtained written in-
formed consent from patients or substitute deci-
sion makers unless the requirement for informed 
consent was waived, according to local standards 
and legislation. An independent data and safety 
monitoring board provided trial oversight. Inter-
im analyses to evaluate the primary outcome were 
performed when enrollment reached 25%, 50%, 
and 75% of the target (Table S1 in the Supple-
mentary Appendix).
Selection of Patients
Patients were eligible if they were 18 years or 
older and had been admitted to an ICU with kid-
ney dysfunction (serum creatinine level, ≥1.13 mg 
per deciliter [100 μmol per liter] in women and 
≥1.47 mg per deciliter [130 μmol per liter] in men) 
and severe acute kidney injury that was catego-
rized as stage 2 or 3 of the Kidney Disease: Im-
proving Global Outcomes (KDIGO) classification 
(in which stages range from 1 to 3, with higher 
stages indicating greater severity). This determi-
nation of kidney injury was defined by a doubling 
of the serum creatinine level from baseline, a se-
rum creatinine level of 4 mg per deciliter (354 μmol 
per liter) or more with an increase of 0.3 mg per 
deciliter (27 μmol per liter) from baseline, or a 
urine output of less than 6 ml per kilogram of 
body weight during the preceding 12 hours. The 
exclusion criteria were focused on emergency 
indications, previous renal-replacement therapy, 
advanced chronic kidney disease, and uncom-
mon causes of acute kidney injury (as detailed in 
Table S2). The presence of all the inclusion crite-
ria and none of the first eight exclusion criteria 
established provisional eligibility (Fig. S1).
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To confirm full eligibility, patients’ attending 
physicians were asked to affirm clinical equi-
poise by noting the absence of any circumstances 
that would mandate either immediate initiation 
of renal-replacement therapy or a deferral of such 
therapy because of clinical judgment regarding 
the likelihood of imminent recovery of kidney 
function. After a determination of full eligibility, 
a 12-hour window was allotted for consent (as 
applicable), randomization, and the initiation 
of renal-replacement therapy for patients in the 
accelerated-therapy group.
At baseline, we evaluated patients using the 
Simplified Acute Physiology Score (SAPS) II on a 
scale that ranges from 0 to 163, with higher 
scores indicating more severe disease and a 
higher risk of death. Patients were also evaluated 
with the Sequential Organ Failure Assessment 
(SOFA) on a scale that ranges from 0 to 24, with 
higher scores indicating more severe disease and 
a higher risk of death.
Randomization and Interventions
Patients were randomly assigned in a 1:1 ratio to 
receive a strategy of accelerated or standard ini-
tiation of renal-replacement therapy. Random-
ization with variable block size (2 and 4) and site 
stratification were implemented with the use of 
a centralized Web-based platform.
In the accelerated-strategy group, clinicians 
were to start renal-replacement therapy as soon 
as possible and within 12 hours after patients 
had met full eligibility criteria. In the standard-
strategy group, clinicians were discouraged from 
initiating renal-replacement therapy until the 
development of one or more of the following 
criteria: a serum potassium level of 6.0 mmol or 
more per liter, a pH of 7.20 or less or a serum 
bicarbonate level of 12 mmol per liter or less, 
evidence of severe respiratory failure based on a 
ratio of the partial pressure of arterial oxygen to 
the fraction of inspired oxygen of 200 or less and 
clinical perception of volume overload, or persis-
tent acute kidney injury for at least 72 hours af-
ter randomization. For patients in the standard-
strategy group, clinicians were not obligated to 
initiate renal-replacement therapy. Similarly, cli-
nicians had discretion to initiate such therapy at 
any time if they perceived that deferral was no 
longer in the patient’s best interest.
The protocol provided recommendations for 
the delivery of renal-replacement therapy that 
aligned with recognized international guide-
lines.13 Discontinuation of renal-replacement 
therapy occurred at the time of recovery of kid-
ney function, withdrawal of life-sustaining sup-
port, or death.
Outcomes
The primary outcome was death from any cause 
at 90 days after randomization. Key secondary 
outcomes at 90 days were dependence on renal-
replacement therapy; a composite of death or 
dependence on renal-replacement therapy; and a 
major adverse kidney event, which was defined 
as death, dependence on renal-replacement ther-
apy, or a sustained reduction in kidney function 
(i.e., an estimated glomerular filtration rate 
[eGFR] of <75% of the baseline value14). Addi-
tional prespecified secondary outcomes included 
death in the ICU at 28 days or during hospital-
ization; the number of days free of renal-replace-
ment therapy at 90 days; the number of ventilator-
free and vasoactive-free days at 28 days4,15; the 
length of hospitalization and hospitalization-free 
days at 90 days; and health-related quality-of-
life, as assessed at 90 days by means of the 
European Quality of Life–5-Dimensions 5-Level 
questionnaire (EQ-5D-5L; scores range from 0 to 
100, with higher scores indicating a better qual-
ity of life).16
Adverse events related to renal-replacement 
therapy and vascular access were reported through 
14 days among all the patients who had under-
gone randomization and remained in the ICU. 
All serious adverse events were reviewed by the 
cochairs of the trial and by the chair of the data 
and safety monitoring board within 48 hours 
after notification.
Statistical Analysis
We performed all analyses in accordance with 
the published statistical analysis plan using a 
modified intention-to-treat principle after the 
exclusion of patients who had withdrawn con-
sent, had been lost to follow-up, or had under-
gone randomization but had subsequently been 
found to be ineligible.11 On the basis of an as-
sumed 90-day mortality of 40% in the standard-
strategy group, we calculated that the enrollment 
of 2866 patients would provide a power of 90% 
to detect a 15% relative between-group differ-
ence (absolute difference, 6 percentage points) 
in the primary outcome at a two-sided signifi-
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cance level of 0.05, while allowing for 3% attri-
tion (withdrawal of consent, loss to follow-up, or 
crossover).6,17 To compensate for such attrition, 
we revised recruitment to 3000 patients. In the 
United Kingdom, enrollment was extended to 
meet local recruitment targets. The expansion in 
recruitment was approved by the data and safety 
monitoring board.
We evaluated the primary outcome of death at 
90 days using a chi-square test, with the results 
reported as a relative risk and absolute risk dif-
ference with 95% confidence intervals. Death at 
90 days was also reported in an adjusted logis-
tic-regression analysis as an odds ratio with 95% 
confidence intervals and in a Kaplan–Meier time-
to-event analysis in which data were censored at 
90 days and compared with the use of a log-rank 
test. We performed prespecified exploratory 
analyses of the primary outcome (Table S3) and 
conducted prespecified subgroup analyses of the 
primary outcome for six variables: sex, baseline 
eGFR, baseline SAPS II, surgical admission, the 
presence of sepsis, and geographic region.18
We reported secondary outcomes — includ-
ing dependence on renal-replacement therapy, 
a composite of death or dependence on renal-
replacement therapy, and a major adverse kidney 
event at 90 days — as unadjusted relative risks 
with 95% confidence intervals and performed 
between-group comparisons using a chi-square 
test. We used inverse probability weighting and 
multinomial regression to account for postran-
domization selection bias when evaluating con-
tinuing dependence on renal-replacement therapy 
(Table S3). We used a t-test to compare serum 
creatinine levels and eGFR values among survi-
vors at 90 days. We calculated medians and in-
terquartile ranges to summarize the number of 
days that patients were alive and free of renal-
replacement therapy, the use of vasoactive drugs 
or mechanical ventilation, ICU stay, hospital stay, 
and quality of life according to treatment group. 
We used linear regression to perform between-
group comparisons and reported the results as 
mean differences and 95% confidence intervals. 
The statistical analysis plan did not include a 
provision that secondary analyses would be cor-
rected for multiple comparisons.11 As such, the 
95% confidence intervals have not been adjusted 
for multiplicity and should not be used to infer 
definitive treatment effects for secondary out-
comes. All statistical analyses were performed 
with the use of Stata software, version 15, and 
R software, version 3.6.2.19
R esult s
Patients
From October 2015 through September 2019, a 
total of 11,852 patients met provisional eligibility. 
Of these patients, 3019 were randomly assigned 
to receive either an accelerated strategy for the 
initiation of renal-replacement therapy (1512 
patients) or a standard strategy (1507 patients) 
(Fig. S2). The number of patients who were sub-
sequently determined to be ineligible to partici-
pate were 31 (2.1%) in the accelerated-strategy 
group and 19 (1.3%) in the standard-strategy 
group (Table S4). In the accelerated-strategy group, 
9 patients (0.6%) withdrew consent and 7 (0.5%) 
were lost to follow-up; the corresponding num-
bers in the standard-strategy group were 18 (1.2%) 
and 8 (0.5%). Thus, 2927 patients (1465 in the 
accelerated-strategy group and 1462 in the stan-
dard-strategy group) were included in the modi-
fied intention-to-treat analysis.
Baseline characteristics were well balanced in 
the two groups (Table 1 and Table S5). In the 
entire population, chronic kidney disease was 
present in 1284 patients (43.9%); 965 patients 
(33.0%) had been admitted to undergo surgery, 
1689 patients (57.7%) had sepsis, and the mean 
(±SD) SAPS II and SOFA scores were 58.8±17.4 
and 11.7±3.6, respectively.
Initiation of Renal-Replacement Therapy
In the accelerated-strategy group, renal-replace-
ment therapy was initiated at a median of 6.1 hours 
(interquartile range, 3.9 to 8.8) after the deter-
mination of full eligibility in 1418 of 1465 pa-
tients (96.8%). In the standard-strategy group, 
such therapy was initiated in 903 of 1462 pa-
tients (61.8%) at a median of 31.1 hours (inter-
quartile range, 19.0 to 71.8) after the determina-
tion of full eligibility (Fig. S3). The characteristics 
of the patients at the time of renal-replacement 
therapy and features of the initial prescription 
are provided in Tables S6 and S7. Among the 
patients in the standard-strategy group who un-
derwent renal-replacement therapy, 597 of 903 
(66.1%) fulfilled at least one prespecified indica-
tion for the initiation of such therapy. At the 
time of initiation, the SOFA score, serum creati-
nine level, blood urea nitrogen level, and positive 
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Age — yr 64.6±14.3 64.7±13.4
Female sex — no. (%) 470 (32.1) 467 (31.9)
Weight — kg 88.0±27.4 88.0±25.1
Serum creatinine — mg/dl† 1.4±1.0 1.3±1.0
Estimated glomerular filtration rate — ml/min/1.73 m2‡ 66.0±29.8 67.3±29.8
Preexisting conditions — no./total no. (%)
Chronic kidney disease 658/1465 (44.9) 626/1462 (42.8)
Hypertension 814/1465 (55.6) 823/1462 (56.3)
Diabetes mellitus 439/1465 (30.0) 459/1461 (31.4)
Heart failure 204/1465 (13.9) 204/1461 (14.0)
Coronary artery disease 320/1465 (21.8) 328/1461 (22.5)§
Liver disease 172/1465 (11.7) 165/1461 (11.3)
Metastatic cancer 77/1465 (5.3) 84/1462 (5.7)
Hematologic cancer 87/1465 (5.9) 83/1462 (5.7)
HIV infection or AIDS 13/1465 (0.9) 13/1462 (0.9)
Admission category — no. (%)
Scheduled surgery 207 (14.1) 184 (12.6)
Unscheduled surgery 285 (19.5) 289 (19.8)
Medical 973 (66.4) 989 (67.6)
Hospital‑acquired risk factor for AKI in previous wk  
— no./total no. (%)
Cardiopulmonary bypass 112/1465 (7.6) 118/1462 (8.1)
Aortic aneurysm repair 71/1465 (4.8) 74/1461 (5.1)
Other vascular surgery 76/1465 (5.2) 77/1462 (5.3)
Major trauma 62/1465 (4.2) 55/1462 (3.8)
Obstetric complication 5/1465 (0.3) 5/1462 (0.3)
Exposure to radiocontrast material 382/1463 (26.1) 375/1460 (25.7)
Receipt of aminoglycoside 154/1463 (10.5) 148/1458 (10.2)
Receipt of amphotericin B 9/1464 (0.6) 12/1460 (0.8)
Clinical condition at randomization
Sepsis — no. (%) 855 (58.4) 834 (57.0)
Septic shock — no. (%) 640 (43.7) 643 (44.0)
SAPS II value¶ 58.1±17.4 59.4±17.4
SOFA score‖ 11.6±3.6 11.8±3.6
Mechanical ventilation — no. (%) 1103 (75.3) 1148 (78.5)
Vasoactive support — no. (%) 1008 (68.8) 1052 (72.0)
Serum creatinine — mg/dl 3.6±1.7 3.4±1.6
Serum potassium — mmol/liter 4.5±0.8 4.5±0.8
Serum bicarbonate — mmol/liter 19.7±4.7 19.5±4.5
Median urinary output (IQR) — ml/24 hr** 450 (190–945) 478 (187–975)
Oliguria or anuria — no./total no. (%)†† 647/1415 (45.7) 618/1420 (43.5)
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fluid balance were higher among the patients in 
the standard-strategy group than among those 
in the accelerated-strategy group.
Primary Outcome
In the modified intention-to-treat analysis, death 
at 90 days occurred in 643 patients (43.9%) in 
the accelerated-strategy group and in 639 (43.7%) 
in the standard-strategy group (relative risk, 1.00; 
95% confidence interval [CI], 0.93 to 1.09), for 
an absolute risk difference of 0.2 percentage 
points (95% CI, −0.3 to 0.4; P=0.92) (Table 2, 
Fig. 1, and Fig. S4). Results were similar in the 
adjusted analysis (adjusted odds ratio, 1.05; 
95% CI, 0.90 to 1.23).
Secondary Outcomes
Among the patients who were alive at 90 days, 
continued dependence on renal-replacement 
therapy was determined in 85 of 814 (10.4%) in 
the accelerated-strategy group and in 49 of 815 
(6.0%) in the standard-strategy group (relative 
risk, 1.74; 95% CI, 1.24 to 2.43). This result was 
robust after inverse probability weighting and in 
a multinomial analysis (Table S8).
There was no meaningful between-group dif-
ference in the composite of death or dependence 
on renal-replacement therapy, major adverse kid-
ney events at 90 days, death in the ICU at 28 days, 
or length of hospitalization (Table 2). In addi-
tion, there were no substantial between-group 
differences in the causes of death (Table S9). In 
each group, patients had a similar number of days 
free of renal-replacement therapy at 90 days; 
there were marginally fewer days of renal-replace-
ment therapy among the patients in the acceler-
ated-strategy group than among those in the 
standard-strategy group (−0.48 days; 95% CI, 
−0.82 to −0.14). Patients in the accelerated-
strategy group had a shorter ICU stay than those 
in the standard-strategy group, but there was no 
evidence of large between-group differences in 
the number of ventilator-free days, vasoactive-free 
days, or ICU-free days at 28 days. Patients in the 
accelerated-strategy group had a higher risk of 
rehospitalization (relative risk, 1.23; 95% CI, 
1.02 to 1.49), but there was no evidence of a 
large between-group difference in the number of 
hospitalization-free days at 90 days. Among sur-
vivors, measures of quality of life and functional 
domains were similar.
Subgroup Analyses
There was no evidence of substantial between-
group heterogeneity of treatment effect regarding 
90-day mortality across prespecified subgroups 
(Fig. 2 and Tables S10 and S11). Similarly, there 
was no evidence of substantial heterogeneity of 
treatment effect on 90-day mortality across SAPS 






Median cumulative fluid balance (IQR) — ml‡‡ 2581 (820–5362) 2819 (836–5603)
*  Plus–minus values are means ±SD. Listed are data in the modified intention‑to‑treat population. To convert the values 
for creatinine to micromoles per liter, multiply by 88.4. AIDS denotes acquired immunodeficiency syndrome, AKI 
acute kidney injury, HIV human immunodeficiency virus, and IQR interquartile range.
†  At baseline, the serum creatinine level was defined as the most recent outpatient level obtained during the year pre‑
ceding the current hospitalization. If this value was not available, the lowest serum creatinine level obtained during 
the current hospitalization was used to establish the baseline.
‡  The estimated glomerular filtration rate was calculated with the use of the Chronic Kidney Disease Epidemiology 
Collaboration equation, which incorporates the baseline serum creatinine level, age, sex, and black race.
§  Data in this category were missing for 1 patient in the standard‑strategy group.
¶  Results for the Simplified Acute Physiology Score (SAPS) II range from 0 to 163, with higher scores indicating more 
severe disease and a higher risk of death.
‖  Scores on the Sequential Organ Failure Assessment (SOFA) range from 0 to 24, with higher scores indicating more 
severe disease and a higher risk of death.
**  Data regarding urinary output were available for 2835 of 2927 patients (96.9%) who had collection of data for at least 
24 hours.
††  Oliguria was defined as a urinary output of less than 400 ml per 24‑hour period.
‡‡  Data regarding cumulative fluid balance after admission to an intensive care unit were available for 2738 of 2927 pa‑
tients (93.5%): 1378 in the accelerated‑strategy group and 1360 in the standard‑strategy group..
Table 1. (Continued.)
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Death from any cause at 90 days — no. (%)† 643 (43.9) 639 (43.7) 1.00 (0.93 to 1.09)‡
Secondary outcomes
RRT dependence among survivors at 90 days — no./total no. (%) 85/814 (10.4) 49/815 (6.0) 1.74 (1.24 to 2.43)‡
Death or RRT dependence at 90 days — no./total no. (%) 728/1457 (50.0) 688/1454 (47.3) 1.06 (0.98 to 1.14)‡
Major adverse kidney events at 90 days — no./total no. (%) 867/1131 (76.7) 860/1115 (77.1) 0.99 (0.95 to 1.04)‡
Serum creatinine at 90 days — mg/dl§ 1.20±1.00 1.23±1.00 −0.03 (−0.11 to 0.06)¶
Estimated glomerular filtration rate‖
At 90 days — ml/min/1.73 m2 65±30 64±31 0.31 (−3.88 to 4.49)¶
Reduction of >25% from baseline at 90 days — no./ 
total no. (%)
139/403 (34.5) 172/427 (40.3) 0.86 (0.72 to 1.02)‡
Death from any cause — no./total no. (%)
At any time in the ICU 461/1464 (31.5) 468/1462 (32.0) 0.98 (0.88 to 1.09)‡
At 28 days 538/1465 (36.7) 523/1462 (35.8) 1.03 (0.93 to 1.13)‡
During hospitalization 552/1458 (37.9) 546/1459 (37.4) 1.01 (0.92 to 1.11)‡
Use of health services
Median no. of days of use (IQR)
RRT‑free days at 90 days** 50 (0 to 87) 64 (0 to 90) −2.62 (−5.66 to 0.42)¶
RRT†† 4 (2 to 8) 5 (3 to 9) −0.48 (−0.82 to −0.14)¶
Continuous RRT†† 4 (3 to 8) 5 (3 to 8) −0.40 (−0.78 to −0.02)¶
Sustained low‑efficiency dialysis†† 2 (1 to 4) 2 (1 to 4) 0.15 (−0.65 to 0.96)¶
Intermittent hemodialysis†† 2 (1 to 4) 3 (2 to 5) −0.45 (−0.80 to −0.09)¶
Median length of stay in ICU (IQR) — days
Survivors 9 (5 to 16) 10 (5 to 19) −1.58 (−2.90 to −0.26)¶
Nonsurvivors 7 (3 to 13) 7 (4 to 15) −1.33 (−2.56 to −0.09)¶
Median length of hospital stay (IQR) – days
Survivors 28 (16 to 50) 29 (17 to 54) −1.23 (−3.87 to 1.41)¶
Nonsurvivors 8 (3 to 18) 9 (4 to 19) −0.99 (−2.66 to 0.67)¶
Median no. of ventilator‑free days at 28 days (IQR) 13 (0 to 24) 12 (0 to 24) 0.50 (−0.34 to 1.35)¶
Median no. of days free of vasoactive agents at 28 days (IQR) 21 (0 to 26) 20 (0 to 26) 0.31 (−0.57 to 1.18)¶
Median no. of days out of ICU at 28 days (IQR) 8 (0 to 21) 4 (0 to 20) 0.69 (−0.06 to 1.43)¶
Median no. of days out of hospital at 90 days (IQR) 10 (0 to 65) 9 (0 to 64) 0.55 (−1.82 to 2.91)¶
Rehospitalization at 90 days — no./total no. (%) 191/913 (20.9) 156/916 (17.0) 1.23 (1.02 to 1.49)‡
Health-related quality of life
Median score on EQ‑5D‑5L at 90 days (IQR)
Descriptive system‡‡
Mobility 2 (1 to 3) 2 (1 to 3) −0.07 (−0.23 to 0.08)¶
Self care 1 (1 to 3) 1 (1 to 3) −0.10 (−0.25 to 0.05)¶
Usual activities 2 (1 to 3) 2 (1 to 4) −0.15 (−0.31 to 0.01)¶
Pain or discomfort 2 (1 to 3) 2 (1 to 3) −0.04 (−0.17 to 0.08)¶
Anxiety or depression 1 (1 to 3) 2 (1 to 3) −0.06 (−0.19 to 0.07)¶
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EQ‑VAS§§ 70 (50 to 80) 70 (50 to 80) 0.11 (−2.55 to 2.76)¶
Score of >4 on Clinical Frailty Scale at 90 days — no. (%)¶¶ 213/655 (32.5) 227/647 (35.1) 0.93 (0.80 to 1.08)‡
*  Plus–minus values are means ±SD. ICU denotes intensive care unit, and RRT renal‑replacement therapy.
†  P = 0.92 for the primary outcome. P values were not calculated for the secondary outcomes because comparisons were not adjusted for 
multiple comparisons.
‡  This value is expressed as a relative risk.
§  Data regarding serum creatinine levels are for survivors at 90 days who were not dependent on kidney‑replacement therapy. Of these 1511 
patients, data were available for 830 (54.9%): 403 patients in the accelerated‑strategy group and 427 patients in the standard‑strategy group.
¶  This value is expressed as a mean difference.
‖  The estimated glomerular filtration rate was calculated with the Chronic Kidney Disease Epidemiology Collaboration equation.
**  Data regarding RRT‑free days are provided for 2900 of 2927 (99.0%) patients: 1448 in the accelerated‑strategy group and 1452 in the 
standard‑strategy group.
††  Included in this category are patients who received renal‑replacement therapy.
‡‡  On the European Quality of Life–5‑Dimensions 5‑Level questionnaire (EQ‑5D‑5L), scores for each of the five domains of the descriptive 
system range from 1 to 5, with higher scores representing greater impairment or worse function. Scores at 90 days were available for 1164 
of 1645 patients (70.8%) for the mobility domain (581 patients in the accelerated‑strategy group and 583 patients in the standard‑strategy 
group); 1165 of 1645 (70.8%) for the self‑care domain (582 patients and 583 patients, respectively); 1163 of 1645 (70.7%) for the usual 
activities domain (581 patients and 582 patients, respectively); 1162 of 1645 (70.6%) for the pain or discomfort domain (580 patients and 
582 patients, respectively); and 1153 of 1645 (70.1%) for the anxiety or depression domain (576 patients and 577 patients, respectively).
§§  Scores on the Visual Analogue Scale of the EQ‑5D‑5L questionnaire (EQ‑VAS) range from 0 to 100, with higher scores indicating better 
health. EQ‑VAS scores were available for 1103 of 1645 survivors (67.0%) at 90 days: 555 patients in the accelerated‑strategy group and 548 
in the standard‑strategy group.
¶¶  Scores on the Clinical Frailty Scale range from 1 to 9, with higher scores indicating a higher degree of frailty. A score of more than 4 is the 
threshold for the definition of frailty. Scores on this scale at 90 days were available for 1302 of 1645 survivors (79.1%).
Table 2. (Continued.)
Figure 1. Kaplan–Meier Estimates of Survival at 90 Days.
In the modified intention‑to‑treat analysis, death at 90 days occurred in 643 patients (43.9%) in the group that re‑
ceived an accelerated strategy for renal‑replacement therapy (RRT) and in 639 (43.7%) in the group that received a 
standard strategy, for an absolute risk difference of 0.2 percentage points (P = 0.92). P = 0.75 for the between‑group 
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Sensitivity Analysis of the Primary Outcome
In the as-treated analysis, there was no evidence 
of a between-group difference in 90-day mortal-
ity. Death was reported in 623 of 1418 patients 
(43.9%) in the accelerated-strategy group and in 
659 of 1509 (43.7%) in the standard-strategy 
group (unadjusted odds ratio, 1.01; 95% CI, 0.87 
to 1.17).
Adverse Events
Adverse events occurred in 346 of 1503 patients 
(23.0%) in the accelerated-strategy group and in 
245 of 1489 patients (16.5%) in the standard-
strategy group (risk ratio, 1.40; 95% CI, 1.21 to 
1.62; P<0.001) (Table 3). Hypotension and hypo-
phosphatemia were the most common adverse 
events with a significant between-group differ-
ence. There was no difference in serious adverse 
events between the two strategies.
Discussion
In this large, multinational, randomized trial, 
critically ill patients with severe acute kidney 
injury who received an accelerated strategy for 
the initiation of renal-replacement therapy did 
not have a lower risk of death at 90 days than 
those who received a standard strategy. This 
finding clarifies a long-standing clinical dilem-
ma regarding the treatment strategy for criti-
cally ill patients with acute kidney injury who 
have no overt complications that would mandate 
the immediate initiation of renal-replacement 
therapy.20 Observational studies using various bio-
chemical thresholds as surrogates for the timing 
of initiation and a single-center randomized trial 
that enrolled primarily surgical patients suggest-
ed that earlier renal-replacement therapy resulted 
in a lower mortality than delayed therapy.7,21-23 
Figure 2. Subgroup Analyses.
Shown is a forest plot of the risk of the primary outcome (death from any cause at 90 days) in the accelerated‑strategy group and the 
standard‑strategy group. The size of the square representing the odds ratio reflects the relative number of patients in each subgroup. 
 Results for the Simplified Acute Physiology Score (SAPS) II range from 0 to 163, with higher scores indicating more severe disease and  
a higher risk of death. GFR denotes glomerular filtration rate, and ICU intensive care unit.
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Conversely, two multicenter, randomized trials, 
including one that exclusively involved patients 
with septic shock, did not show a lower risk of 
death with an early strategy than with a delayed 
strategy for the initiation of renal-replacement 
therapy.4,5 In these two trials, eligibility was tied 
to fulfilling consensus-defined serum creatinine 
levels and urine-output thresholds for severe 
acute kidney injury, with renal-replacement ther-
apy initiated promptly after this determination in 
the early-therapy group. In the delayed-therapy 
group, the initiation of renal-replacement ther-
apy was mandated for patients in whom acute 
kidney injury persisted for 48 to 72 hours or in 
whom metabolic or f luid complications devel-
oped. In the two trials, a sizable percentage of 
patients in the delayed-therapy group did not 
receive renal-replacement therapy because they 
either recovered kidney function or died.
In our trial, we aimed to enrich our patient 
population by incorporating clinical equipoise to 
guide eligibility, rather than relying on defined 
intervals after the patients fulfilled consensus 
criteria for severe acute kidney injury. This pro-
cess excluded more than 7000 patients who had 
been rated by clinicians as being appropriate can-
didates for emergency renal-replacement therapy 
or likely to have imminent recovery of kidney 





(N = 1489) P Value†
Patients Events Patients Events
no. (%)
no. (per 1000 
patient-mo) no. (%)
no. (per 1000 
patient-mo)
Any adverse event 346 (23.0) 556 (195.7) 245 (16.5) 364 (128.1) <0.001
Associated with renal‑replacement therapy
Hypotension 131 (8.7) 188 (66.2) 83 (5.6) 112 (39.4) 0.001
Arrhythmia 37 (2.5) 45 (15.8) 23 (1.5) 29 (10.2) 0.07
Seizure 1 (0.1) 1 (0.4) 0 0 1.00
Bleeding 4 (0.3) 4 (1.4) 1 (0.1) 1 (0.4) 0.37
Allergic reaction 1 (0.1) 1 (0.4) 1 (0.1) 1 (0.4) 1.00
Decreased phosphate (<0.5 mmol/liter) 112 (7.5) 124 (43.7) 62 (4.2) 68 (23.9) <0.001
Decreased potassium (<3.0 mmol/liter) 34 (2.3) 43 (15.1) 34 (2.3) 40 (14.1) 0.97
Decreased ionized calcium (<0.90 mmol/
liter)
80 (5.3) 102 (35.9) 66 (4.4) 80 (28.1) 0.26
Associated with use of a dialysis catheter
Pneumothorax or hemothorax 4 (0.3) 5 (1.8) 2 (0.1) 2 (0.7) 0.69
Bleeding 6 (0.4) 6 (2.1) 4 (0.3) 4 (1.4) 0.75
Thrombus (as confirmed on ultrasonog‑
raphy)
3 (0.2) 3 (1.1) 5 (0.3) 5 (1.8) 0.51
Arterial puncture 3 (0.2) 3 (1.1) 2 (0.1) 2 (0.7) 1.00
Bloodstream infection 7 (0.5) 7 (2.5) 1 (0.1) 1 (0.4) 0.07
Other 21 (1.4) 24 (8.4) 20 (1.3) 19 (6.7) 0.90
Serious adverse events — no. (%) 15 (1.0) 17 (6.0) 8 (0.5) 8 (2.8) 0.15
*  Listed are data through 14 days for 2992 of 3019 patients (99.1%) who had undergone randomization and remained in the ICU; not includ‑
ed are 27 patients for whom consent had been withdrawn. Individual investigators made the determination of whether the adverse event 
was related to renal‑replacement therapy or the use of a dialysis catheter. To convert the values for phosphate to milligrams per deciliter, 
divide by 0.3229. To convert the values for potassium to milligrams per deciliter, divide by 0.2558. To convert the values for ionized calcium 
to milligrams per deciliter, divide by 0.250.
†  P values are for the between‑group difference in the percentage of patients with a specific adverse event and have not been adjusted for 
multiple comparisons.
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function. Furthermore, triggers for the initiation 
of renal-replacement therapy in our standard-
strategy group were not directed by thresholds 
for severity of acute kidney injury or defined 
time intervals.4,5,7 Our trial also provided evidence-
informed recommendations for the prescription 
of renal-replacement therapy and adopted a 
pragmatic approach to reflect current practice. 
Similar to our pilot work and previous trials, a 
substantial percentage of the patients in the 
standard-strategy group did not receive renal-
replacement therapy, which highlights the chal-
lenge faced by clinicians in predicting worsening 
acute kidney injury in critically ill patients.4-6 
Despite these differences in trial design, we did 
not observe a lower 90-day mortality with an 
accelerated strategy, a finding that was robust 
in adjusted and sensitivity analyses.
A greater percentage of survivors who received 
the accelerated strategy were dependent on renal-
replacement therapy at 90 days and had adverse 
events. This finding suggests that greater expo-
sure to renal-replacement therapy, possibly mod-
ified according to baseline risk (e.g., the pres-
ence of chronic kidney disease) or mediated by 
iatrogenic factors (e.g., hypotension), may com-
promise kidney repair and the return of endog-
enous kidney function.24-26
There are noteworthy strengths of our trial. 
First, our large sample size afforded the ability 
to detect a clinically important difference in mor-
tality between accelerated and standard initia-
tion of renal-replacement therapy. Second, the 
recruitment of patients from a wide spectrum of 
ICUs in several countries enabled broad general-
izability. Third, our trial deliberately enrolled 
patients for whom the decision on the initiation 
of renal-replacement therapy was genuinely un-
certain by excluding those for whom treating 
clinicians felt a lack of equipoise.6
Our trial also has limitations. First, we recog-
nize that equipoise is relatively subjective and 
that the perception of equipoise may be modi-
fied by individual clinician bias. By allowing 
clinicians to use their judgment in confirming 
full eligibility, we may have introduced patient 
heterogeneity into the trial. However, we did not 
observe evidence of substantial heterogeneity of 
treatment effect across subgroups, including ill-
ness severity and geographic region. Second, 
although the protocol provided recommenda-
tions on when to start renal-replacement therapy 
in patients in the standard-strategy group, the 
broad discretion that was afforded to clinicians 
may have resulted in variable initiation times. 
Third, adverse events were more frequent with 
the accelerated strategy, although this result may 
be partly attributed to the prespecified focus on 
reporting of events related to renal-replacement 
therapy and to the larger number of patient-days 
of such therapy with this strategy.
In conclusion, in critically ill patients with 
severe acute kidney injury, an accelerated strat-
egy for the initiation of renal-replacement ther-
apy did not result in a lower mortality at 90 days 
than a standard strategy.
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